ArticleHaematologica2021

A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.

Qing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.